Sign in

Private company

INFINITY PHARMACEUTICALS, INC.

INFINITY PHARMACEUTICALS, INC. is an American pharmaceutical preparations company based in Cambridge.2

Last updated Oct 21, 2026.

Overview

  • IndustryPharmaceutical Preparations2
  • HeadquartersCambridge, United States2
  • Incorporated inDE3
  • Business address1100 Massachusetts Avenue, Floor 4, Cambridge, Ma 021383
  • Filer categoryNon-accelerated filer, Smaller reporting company3
  • Legal formCorporation2
  • LEI529900A03D1G15M8WM722
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressc/o The Corporation Trust Company, Corporation Trust Center 1209 Orange St, 19801 Wilmington, United States2
  • Registered withDivision of Corporations, Department of State, 32269752

See how the biggest companies compare on our leaderboards

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2022

-1729.4%Operating margin4
-1711.1%Net margin4
39.6%Revenue growth, 20224
-$42.4MFree cash flow4

Where the money goes

Where each dollar of revenue went, fiscal 2022

  • Research and development100¢$32.4M

Out of $2.6M in revenue.4 The company lost money this year.

Financial statements

Revenue56784$2.6M in 2022−57% since 2017
0$10.0M$20.0M$30.0M2017: $6.0M$6.0M20172018: $22.1M$22.1M2018+269%2019: $3.0M$3.0M2019−86%2020: $1.7M$1.7M2020−44%2021: $1.9M$1.9M2021+8%2022: $2.6M$2.6M2022+40%
Operating income956784-$44.8M in 2022+45% since 2016
-$60.0M-$40.0M-$20.0M02016: -$30.9M-$30.9M20162017: -$36.4M-$36.4M2017+18%2018: -$11.9M-$11.9M2018−67%2019: -$45.7M-$45.7M2019+283%2020: -$38.5M-$38.5M2020−16%2021: -$45.1M-$45.1M2021+17%2022: -$44.8M-$44.8M2022−1%
Net income956784-$44.4M in 2022+47% since 2016
-$60.0M-$40.0M-$20.0M02016: -$30.1M-$30.1M20162017: -$41.8M-$41.8M2017+39%2018: -$11.3M-$11.3M2018−73%2019: -$47.1M-$47.1M2019+318%2020: -$40.5M-$40.5M2020−14%2021: -$45.3M-$45.3M2021+12%2022: -$44.4M-$44.4M2022−2%
Fiscal year2016201720182019202020212022
Revenue$6.0M5$22.1M6$3.0M7$1.7M8$1.9M4$2.6M4
Research and development$119.6M9$20.8M5$19.8M6$27.1M7$26.8M8$31.6M4$32.4M4
Operating expenses$46.9M4$47.4M4
Operating income-$30.9M9-$36.4M5-$11.9M6-$45.7M7-$38.5M8-$45.1M4-$44.8M4
Interest$1.2M9$1.0M5$93.0K6$2.6M6
Income tax$09-$720.0K5$06-$54.0K7$08$04$04
Net income-$30.1M9-$41.8M5-$11.3M6-$47.1M7-$40.5M8-$45.3M4-$44.4M4
Earnings per share-$0.688-$0.534-$0.504
Earnings per share (diluted)-$0.688-$0.534-$0.504
Shares (weighted, basic)85.6M shares489.2M shares4
Shares (weighted, diluted)85.6M shares489.2M shares4

Compare INFINITY PHARMACEUTICALS, INC. with another company

Corporate structure

INFINITY PHARMACEUTICALS, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of INFINITY PHARMACEUTICALS, INC.

  • INFINITY PHARMACEUTICALS, INC. Cambridge, Massachusetts, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What INFINITY PHARMACEUTICALS, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$4.1M4 Dec 31, 2022$4.1M4 Dec 31, 2021+0.4%
Accumulated depreciation$3.3M4 Dec 31, 2022$2.9M4 Dec 31, 2021+16.1%
Property and equipment, net$800.0K4 Dec 31, 2022$1.2M4 Dec 31, 2021−35.5%
Operating-lease assets (leased space)$697.0K4 Dec 31, 2022$1.1M4 Dec 31, 2021−34.5%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$38.3M4 Dec 31, 2022$80.7M4 Dec 31, 2021−52.5%
Marketable securities, current$08 Dec 31, 2021$5.5M8 Dec 31, 2020−100.0%

Leadership

Who has led INFINITY PHARMACEUTICALS, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Steven H. Holtzman2006–2009
  2. Adelene Q. Perkins2010–2022

Chair

  1. Steven H. Holtzman2007–2010

President

  1. Julian Adams2006–2016
  2. Steven H. Holtzman2007–2008
  3. Adelene Q. Perkins2015–2016
  4. Lawrence E. Bloch2017–2022

Chief financial officer

  1. Adelene Q. Perkins2006–2007
  2. Lawrence E. Bloch2012–2016
2010201520202025
Board members and other officers (45)

Former names

  • DISCOVERY PARTNERS INTERNATIONAL INCJun 23, 2000 to Sep 11, 20063

Timeline

  1. Sep 29, 20238-K Bankruptcy or receivership; Executive or director change64
  2. Sep 13, 20238-K Listing notice or transfer65
  3. Sep 11, 20238-K Listing notice or transfer66
  4. Sep 1, 20238-K Exit or restructuring costs; Executive or director change; Other events67
  5. Jul 25, 20238-K Exit or restructuring costs; Executive or director change; Other events68
  6. Jul 24, 20238-K Ended a material agreement; Other events69
  7. Jul 14, 20238-K Shareholder vote70
  8. Jul 3, 20238-K Other events71
  9. Jun 30, 20238-K Listing notice or transfer72
  10. Jun 20, 20238-K Regulation FD disclosure73
  11. Apr 7, 20238-K Listing notice or transfer74
  12. Mar 28, 20238-K Results of operations75
  13. Jan 7, 2010New chief executive Adelene Q. Perkins becomes CEO12
  14. Sep 13, 2006New chief executive Steven H. Holtzman becomes CEO13

Calendar

When it reported results

  1. Mar 28, 2023Reported quarterly or annual results75
  2. Nov 14, 2022Reported quarterly or annual results76
  3. Aug 9, 2022Reported quarterly or annual results77
  4. May 3, 2022Reported quarterly or annual results78
  5. Mar 29, 2022Reported quarterly or annual results79
  6. Jan 5, 2022Reported quarterly or annual results80
  7. Nov 2, 2021Reported quarterly or annual results81

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

77 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 24 major events, 15 insider forms, 9 large holders, 21 other. The latest 20:

  1. Nov 20, 202325-NSE EDGAR
  2. Sep 29, 20238-K EDGAR
  3. Sep 13, 20238-K EDGAR
  4. Sep 12, 20234 FORM 4 SUBMISSION EDGAR
  5. Sep 11, 20238-K EDGAR
  6. Sep 1, 20238-K EDGAR
  7. Aug 10, 202310-Q EDGAR
  8. Jul 25, 20238-K EDGAR
  9. Jul 24, 20238-K EDGAR
  10. Jul 14, 20238-K EDGAR
  11. Jul 10, 2023DEFA14A EDGAR
  12. Jul 5, 2023DEFA14A EDGAR
  13. Jul 3, 2023425 EDGAR
  14. Jul 3, 20238-K EDGAR
  15. Jul 3, 2023DEFA14A EDGAR
  16. Jun 30, 20238-K EDGAR
  17. Jun 29, 2023DEFA14A EDGAR
  18. Jun 27, 2023DEFA14A EDGAR
  19. Jun 21, 2023DEFA14A EDGAR
  20. Jun 20, 2023DEFA14A EDGAR

The 77 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

2 open-market trades by officers, directors and large owners since October 2021: 0 buys and 2 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Sep 12, 2023Perkins Adelene QDirectorSale410,196$0.07$28.7KForm 4
Aug 2, 2022Peluso StephaneChief Scientific OfficerSale14,994$0.66$9.9KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

SEC filer profile

How INFINITY PHARMACEUTICALS, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARINFINITY PHARMACEUTICALS, INC.1
  • CIK0001113148
  • Employer ID (EIN)33-06557061
  • Filer statusNon-accelerated filer<br>smaller reporting company1
  • Incorporated inDelaware1
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • Business address1100 Massachusetts Avenue, Floor 4, Cambridge, MA 021381
  • Phone61745310001
  • Shares outstanding90,761,081 as of Aug 3, 202311
  • Public float$55.0M as of Jun 30, 20224
  • On EDGAR sinceMay 9, 20001
  • Filings1,187 in all: 4 (392), 8-K (266), SC 13G/A (91), 10-Q (70), 3 (54), SC 13G (50), 425 (36), DEF 14A (23)1
    All 45 form types

    10-K (22), S-8 (17), DEFA14A (16), CORRESP (13), SC 13D/A (13), UPLOAD (13), CT ORDER (12), ARS (11), 424B5 (10), EFFECT (10), S-3 (10), 5 (8), 4/A (5), S-1/A (5), 10-Q/A (3), 424B3 (3), FWP (3), PRE 14A (3), S-4/A (3), SC 13D (3), 424B4 (2), 8-A12G (2), 8-K/A (2), S-3/A (2), S-3ASR (2), 10-K/A (1), 10-K405 (1), 25-NSE (1), 3/A (1), 424A (1), 8-A12G/A (1), D (1), DEFM14A (1), REGDEX (1), S-1 (1), S-3MEF (1), S-4 (1)

  • Latest filingsAnnual report (10-K) Mar 28, 2023
    Quarterly report (10-Q) Aug 10, 2023
    Proxy statement (DEF 14A) Apr 25, 2022
    Latest 8-K (8-K) Sep 29, 2023

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
    SEC EDGAROther events
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87